Top 111 medical and healthcare startups in Cambridge
Mar 23, 2026
|
Like
28
1
Funding: $1.8B
Nuvalent develops targeted therapies targeting clinically proven kinases in oncology. Its drugs are small molecules that precisely interact with the target kinase in the original tumor and the mutated target kinase in the drug-resistant tumor. This allows the drugs to treat both the original tumor and tumors with emerging resistance mutations. Structure-based design technology addresses the issue of kinase selectivity to minimize side effects and ensure durable treatment responses. The company's pipeline includes clinical trials against non-small cell lung cancer and the treatment of brain metastases.
Nuvalent develops targeted therapies targeting clinically proven kinases in oncology. Its drugs are small molecules that precisely interact with the target kinase in the original tumor and the mutated target kinase in the drug-resistant tumor. This allows the drugs to treat both the original tumor and tumors with emerging resistance mutations. Structure-based design technology addresses the issue of kinase selectivity to minimize side effects and ensure durable treatment responses. The company's pipeline includes clinical trials against non-small cell lung cancer and the treatment of brain metastases.
2
Funding: $1.5B
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
3
Funding: $1.4B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
4
Funding: $1.3B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
6
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
7
Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
8
Funding: $931.6M
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
9
Funding: $767M
OpenEvidence is a medical AI company that builds a search engine to support clinicians in making evidence-based decisions.
OpenEvidence is a medical AI company that builds a search engine to support clinicians in making evidence-based decisions.
10
Funding: $656.4M
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
11
Funding: $603.3M
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
12
Funding: $573.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
13
Funding: $550M
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
14
Funding: $537.8M
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
15
Funding: $536.4M
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.
16
Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
17
Funding: $443.6M
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
18
Funding: $442.5M
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
19
Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
20
Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
21
Funding: $407M
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
22
Funding: $405.9M
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
23
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
24
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
25
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
26
Funding: $369.7M
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
28
Funding: $325M
Obsidian Therapeutics develops precision cell and gene therapies to expand the capabilities of adoptive cancer immunotherapy. The company has developed the cytoDRiVE platform, which leverages drug-responsive domains (DRDs) to control protein function using an FDA-approved small molecule, and is continually expands its library of identified DRDs of varying sizes and purposes. The company's lead drug, OBX-115, is an experimental therapy using tumor-infiltrating lymphocytes genetically modified to produce a membrane-bound (non-secreted) cytokine (IL15). Obsidian is conducting a multicenter clinical trial for the treatment of advanced melanoma and non-small cell lung cancer.
Obsidian Therapeutics develops precision cell and gene therapies to expand the capabilities of adoptive cancer immunotherapy. The company has developed the cytoDRiVE platform, which leverages drug-responsive domains (DRDs) to control protein function using an FDA-approved small molecule, and is continually expands its library of identified DRDs of varying sizes and purposes. The company's lead drug, OBX-115, is an experimental therapy using tumor-infiltrating lymphocytes genetically modified to produce a membrane-bound (non-secreted) cytokine (IL15). Obsidian is conducting a multicenter clinical trial for the treatment of advanced melanoma and non-small cell lung cancer.
29
Funding: $321M
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
30
Funding: $313M
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
31
Funding: $309M
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
32
Funding: $305M
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
33
Funding: $304.5M
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
34
Funding: $277.5M
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
35
Funding: $276.8M
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
36
Funding: $272.1M
Black Diamond Therapeutics is focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.
Black Diamond Therapeutics is focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.
37
Funding: $270M
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
38
Funding: $259.3M
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.
39
Funding: $253M
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
40
Funding: $250M
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
41
Funding: $245M
AIRNA develops RNA editing technologies to create medicines for various diseases.
AIRNA develops RNA editing technologies to create medicines for various diseases.
42
Funding: $245M
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
43
Funding: $221M
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
44
Funding: $216.8M
Cognito is developing a therapeutic device, Spectris, which can be prescribed by doctors and used by patients at home to treat Alzheimer's disease by stimulating coordinated neural activity through non-invasive visual and auditory stimulation. The device is designed as a full-size headphones. The pivotal clinical study, which is evaluating Spectris AD therapy for Alzheimer's disease, is currently underway, and the company is preparing to submit an application to the FDA.
Cognito is developing a therapeutic device, Spectris, which can be prescribed by doctors and used by patients at home to treat Alzheimer's disease by stimulating coordinated neural activity through non-invasive visual and auditory stimulation. The device is designed as a full-size headphones. The pivotal clinical study, which is evaluating Spectris AD therapy for Alzheimer's disease, is currently underway, and the company is preparing to submit an application to the FDA.
45
Funding: $211M
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
46
Funding: $199M
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
47
Funding: $193.7M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
48
Funding: $189.2M
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
49
Funding: $180M
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
50
Funding: $178.2M
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
